China’s WuXi Biologics (HK: 2269) has entered into an equity agreement with US pharma giant Pfizer’s (NYSE: PFE) China subsidiary to acquire its state-of-the-art biologics manufacturing facilities, as well as its labor force in Hangzhou, China.
The transaction is expected to close in the first half of 2021, which will immediately boost the commercial drug substance (DS) and drug product (DP) capacities for WuXi Biologics to address surging manufacturing demands.
Both Pfizer and WuXi declined to disclose the deal value, or the products to be made after the transaction closes. However, back in 2016, Pfizer announced that it planned to invest about $350 million in the Hangzhou facility.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze